Trial Profile

A Prospective, Observational, Multicenter Study on the Safety and Efficacy of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2023 Results assessing the effectiveness and safety of apixaban in adults with congenital heart disease patients with atrial arrhythmias, presented at the American Heart Association Scientific Sessions 2023.
28 Aug 2023 Results (n=444 from studies PROTECT-AR and a historical vitamin-K antagonist (VKA) treatment cohort from 2002 to 2014) assessing Safety and efficacy of apixaban for the prevention of thromboembolism in adults with congenital heart disease and atrial arrhythmias presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
20 Jun 2023 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com